Navigation Links
CryoCor Receives FDA Approval for Right Atrial Flutter
Date:8/19/2007

SAN DIEGO, Aug. 2 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today that the U.S. Food and Drug Administration (FDA) has granted pre-market approval (PMA) for its Cardiac Cryoablation System for the treatment of right atrial flutter.

Based on this approval, CryoCor intends to begin selling its cryoablation system in the United States over the next several months. The Company will place an initial focus on console placement in high-volume ablation centers in the U.S. and is currently evaluating its sales and marketing requirements for this strategy. The Company has targeted an initial installed base of approximately 120 to 160 consoles by December 31, 2008, growing to approximately 300 consoles by 2010.

Helen Barold, M.D., Chief Medical Officer of CryoCor, said, "I am extremely pleased with the FDA's decision to approve our Cryoablation System for the treatment of right atrial flutter. There is a large opportunity for treating flutter with cryoablation. Over 200,000 patients per year in the United States are diagnosed with this condition. Many of these patients could benefit from the unique advantages provided by our system, specifically the fact that cryoablation is a less painful way of ablating right atrial flutter as demonstrated by several published studies. "

Ed Brennan, Ph.D., President and Chief Executive Officer of CryoCor, said, "The approval of the PMA for the CryoCor Cryoablation System for the treatment of right atrial flutter by the FDA is a major milestone for the company. We look forward to commencing our sales and marketing efforts and driving utilization of our Cryoablation System. An important element of our strategy is to grow our installed base of consoles, which drives the use of disposables for the treatment of right atrial flutter."

The FDA's decision to approve CryoCor's PMA for right atrial flutter follows an Advisory Panel meeting convened on June 27, 2007. At that panel meeting, the Advisory Panel voted to recommend approval of CryoCor's PMA, with conditions. To comply with these conditions, CryoCor will implement a formal training program for clinical sites, as well as conduct a two-arm registry study of 650 patients collecting safety and long term effectiveness data on the use of its cryoablation system as compared to approved radiofrequency catheters in the treatment of right atrial flutter. CryoCor reported that it does not anticipate significant difficulty in complying with the requirements of the registry study.

About CryoCor

CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of atrial fibrillation, and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com

Forward Looking Statements

The statements in this press release that are not descriptions of historical facts are forward-looking statements that are subject to risks and uncertainties. Such statements are only predictions and reflect the Company's expectations and assumptions as of the date of this press release based on currently available operating, financial, and competitive information. The actual events or results may differ materially from those projected in such forward-looking statements due to a number of factors, including risks associated with the Company's ability to successfully commercialize its Cryoablation System in the United States and elsewhere; risks associated with the Company's dependence on patents and proprietary rights; risks associated with the Company's protection and enforcement of its patents and proprietary rights; risks associated with the development or availability of competitive products or technologies; and the other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update any of these forward- looking statements.

Contacts:

CryoCor The Ruth Group

Gregory J. Tibbitts Nick Laudico / Zack Kubow (investors)

Chief Financial Officer (646) 536-7030 / 7020

(858) 909-2200 nlaudico@theruthgroup.com

gtibbitts@cryocor.com zkubow@theruthgroup.com

Jason Rando (media)

(646) 536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE CryoCor, Inc.

Copyright©2007 PR Newswire.

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017 The Mobile X-Ray product segment is the ... during the forecast period Mobile X-Ray segment is ... mobile X-Ray devices market, which is estimated to be valued ... a CAGR of 7% over the forecast period. Mobile X-Ray ... than US$ 100 Mn in 2017 over 2016. The segment,s ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... 2017 , ... Chicago plastic surgeon, Dr. Anil R. Shah, MD , ... benign bony lump located on the forehead usually attributed to a facial fracture. Their ... pain. Dr. Shah has discovered an approach that is minimally invasive. He is an ...
(Date:4/21/2017)... ... 2017 , ... Young Asset Protection, an insurance provider and ... greater Pittsburgh metropolitan region, is joining forces with the local chapter of the ... , Variety the Children’s Charity is a national organization dedicated to empowering, enabling, ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Patient Advocacy Community of The Beryl Institute ... 2017 Ruth Ravich Patient Advocacy Award in recognition of her extraordinary contributions to ... the award at The Beryl Institute’s annual Patient Experience Conference on March ...
(Date:4/21/2017)... ... April 21, 2017 , ... Crossover Symmetry ... O2X , an active lifestyle company that provides Human Performance Training and education ... police offers, first responders, military officers and others in service through the development ...
(Date:4/21/2017)... ... April 21, 2017 , ... Airway ... new partnership with the highly regarded and well renowned Asian distributor, Discovery Sleep. ... & myTAP PAP Nasal Pillow Mask, and will stabilize and strengthen Airway’s presence ...
Breaking Medicine News(10 mins):